Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Ridker, Paul M; Amarenco, Pierre; Brunell, Robert; Glynn, Robert J; Jukema, J Wouter; Kastelein, John J P; Koenig, Wolfgang; Nissen, Steven; Revkin, James; Santos, Raul D; Schwartz, Pamela F; Yunis, Carla; Tardif, Jean-Claude; Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Investigators 
Titel:
Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events 
Abstract:
Although statins significantly reduce vascular event rates, residual cholesterol risk remains high in many patient groups, including those with known vascular disease as well as in the setting of high-risk primary prevention. Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), prolongs the half-life of hepatic low-density lipoprotein (LDL) receptors, and reduces circulating atherogenic cholesterol levels.The SPIRE program comprises...    »
 
Zeitschriftentitel:
Am Heart J 
Jahr:
2016 
Band / Volume:
178 
Seitenangaben Beitrag:
135-44 
Sprache:
eng 
Print-ISSN:
0002-8703 
TUM Einrichtung:
Klinik für Herz- und Kreislauferkrankungen